Avocado Soy Unsaponifiables
Unsaponifiable of Avocado 100 mg (1 part)
Unsaponifiable of Soybean 200 mg (2 parts)

-Shellfish and Gluten Free
-Dairy Free
-No flavors or GMO

Good news! Arthrocen is available now with a new label design.
Please contact us at if you have any questions or need free samples!

In rheumatology: Treatment of osteoarthritis.

Hypersensitivity to the components of the formula.It is not indicated during pregnancy, lactation, patients with malabsorption syndrome and patients taking anticoagulants.

Patients with hepatic impairment and patients with hyperthyroidism should be under medical supervision, because high doses and prolonged use of the product can affect these patients.

Not used during pregnancy and lactation. Do not take more than the recommended dose.
The effect of Arthrocen ® 300 during lactation has not been evaluated, so it is not recommended.

May occasionally occur with regurgitation reflux symptoms, which can be avoided by taking the capsule into the middle of foods.Occasionally there may be pain in stomach and diarrhea.

It can interfere with the absorption of anticoagulant drugs and interact with MAO inhibitors.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No embryotoxic or teratogenic effect at doses of 10, 100 and 1,000 mg / kg / day in mouse and rabbit but there are slight changes in the skeleton of rabbit at doses of 500 mg / kg.No reported adverse effects on fertility.

DOSAGE AND ADMINISTRATION: Take one capsule daily by mouth with meal.


  • Capsule 300 mg/ 30 and 60 counts.
  • Store at 68 to 77 centigrade (See USP Controlled Room Temperature).
  • Keep out of reach of children.
  • Do not use if safety seal is damaged or missing.
  • Consult a physician before using this product or any other medications and dietary supplements.


Osteoarthritis (OA) is a painful and life-altering disease that severely limits the daily activity of millions of Americans, and is one of the most common causes of disability in the world. With obesity on the rise and the world’s population living longer, the prevalence of OA is expected to increase dramatically in the coming decades, generating burdensome socioeconomic costs.

Osteoarthritis (OA) is a chronic synovial joint disease, characterized by two main features: 1) progressive damage of articular cartilage, bone remodeling and new bone formation (osteophytes and subchondral bone sclerosis), and 2) synovial inflammation and fibrosis of ligaments, tendons, menisci, and capsules. All joints may be affected, but the most commonly involved are knees, hands, and hips (Fig. 1). While chronic OA used to be regarded as a "wear and tear disease," researchers now believe that low grade inflammation and growth of blood vessels and nerves from the subchondral bone into articular cartilage, as well as metabolic disorders, play a major role in disease pathology. Patients with OA suffer from pain, inflammation, and limited joint function. Pharmacological interventions are mostly palliative, focusing on alleviation of symptoms or slowing disease progression until damaged hip or knee joints are eventually replaced.Women are more severely impacted than men by knee osteoarthritis. Differences in knee anatomy (narrower femurs, thinner patellae, larger quadriceps angles, and differences in tibial condylar size), previous knee trauma, genetic and hormonal influences may play a role. Other factors like age, and obesity, are also common factors. In general, women present for treatment in more advanced stages of osteoarthritis and have more debilitating pain than men. Women also have less cartilage volume and greater cartilage wear, and overall differences in mechanical alignment. Current Pharmacologic Therapies.


Preclinical in vitro and in vivo studies have demonstrated that ASUs have beneficial effects on OA. ASU possesses chondroprotective , anabolic and anticatabolic properties. It inhibits the breakdown of cartilage and promotes cartilage repair by inhibiting a number of molecules and pathways implicated in OA.

ASU stimulates the synthesis of collagen and aggrecan by inhibiting inflammatory cytokines such as IL1, IL6, IL8, TNF, and PGE2 through modulation of NF-kappaB .The combination of ASU and epigallocatechin gallate (EGCG, a major component of green tea catechins), affect an array of inflammatory molecules including expression of COX-2 and production of PGE2 in chondrocytes. COX-2 regulates the production of PGE2; both are mediators involved in the process of cartilage breakdown. ASU also inhibits the release and activity of collagenase (MMP2) and stromelysin 1 (MMP3) in cultured chondrocytes, increases tissue inhibitors of metalloproteinases TIMP-1 and inhibits IL-1 induced ERK but not p38 or JNK in chondrocytes in vitro . In vitro studies show that ASU inhibits fibrinolysis by stimulating the

At the clinical level, ASU reduces pain and stiffness while improving function in joints, resulting in decreased dependence on analgesics. ASU efficacy and safety during and post treatment have been assessed in various randomized, double blind, multicenter trials in patients with symptomatic knee or hip OA. Two studies conducted over a 3 month period report that standard treatment with 300 mg/day of ASU improved indices of pain, stiffness, and physical function, as measured by WOMAC, and decreased analgesic drug demanded in patients with OA

A third trial conducted over 6 months reports similarly improved function compared to placebo, measured by the Lequense Functional Index, with persistent effects after termination of treatment. In a 6-month trial on patients with femorotibial gonarthrosis, ASU was as effective as 400 mg of chondroitin sulfate three times per day, as measured by WOMAC. Most recently a three-year randomized trial on patients with hip OA, performed under the ACR criteria (minimum of 1–4 mm hip JSW on the pelvic radiographs), reports excellent safety, but no significant reduction in the mean rate of JSN after one year. However, analyzing the results under different parameters reveals a significant 20% reduction in the rate of progression in patients with severe hip OA (p = 0.04), indicating a potential structure modifying effect of ASU as confirmed in the ERADIAS study.

In a clinical trial of patients with hip OA, the effects of ASU treatment over 3 years were evaluated by radiography to identify joint pathology and disease progression on the structural level. Although JSN was not statistically significant between ASU and placebo treatment, secondary analysis of disease progression, measured by JSN (0.5 mm) or total hip replacements, indicated 20% improvement with ASU (42.2% versus 51.4% of placebo group, p=0.054). Computerized image analysis also showed significant histological differences not detectable by traditional scoring methods.

In sheep, ASU treatment following cartilage insult improved articular integrity, as measured by toluidine blue staining, after 6 months compared to untreated animals. These improvements were the result of decreased catabolism and increased anabolism of cartilage by ASU.Indeed, ASU reduces inflammation mediated cartilage degradation by reducing IL-1, PGE2 and MMP-3 production, while also inducing proteoglycan, non-collagenous protein (NCP) and collagen synthesis within 72 hours of administration to bovine cells in culture. A recent study in patients with nonspecific dorsalgia demonstrated analgesic effect of ASU with positive outcome after one month. Four double-blind placebo-controlled randomized human clinical trials (RCTs) evaluate ASU's impact on knee and hip OA (109). Two of these indicated that ASU treatment decreased NSAID intake over 3 months.


  1. Metabolic effects of avocado/soy unsaponifiables on articular chondrocytes. Evidence Based Complement.
  2. Unsaponifiable constituents of avocado and soya oils. Treatment of certain forms of arthralgia.
  3. Effect of unsaponifiable extracts of avocado and soybean on the collagenolytic action of cultures of human rheumatoid synoviocytes and rabit.
  4. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU)..
  5. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP-2), stromelysin 1 (MMP-3), and tissue inhibitors of matrix metalloproteinase (TIMP- 1 and TIMP-2) secretion by human fibroblast
  6. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU).
  7. Healing of osteochondral defects in canine knee with avocado/soybean unsaponifiables: a morphometric comparative analysis.
  8. Biochemical effects of unsaponifiable lipidic components of avocado and soya bean administered percutaneously on the connective tissue components of hairless rat skin.
  9. Avocado/ soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory.
  10. Expression of pro-inflammatory mediators is inhibited by an avocado/soybean unsaponifiables and epigallocatechin gallate combination.
  11. The possible "chondroprotective" effect of the unsaponifiable constituents of avocado and soya in vivo.
  12. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial.
  13. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study.
  14. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect.
  15. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.
  16. Method of histomorphometric assessment of glycosaminoglycans in articular cartilage.